Phathom Pharmaceuticals (PHAT) Share-based Compensation (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Share-based Compensation data on file, last reported at $5.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $5.5 million, changed 0.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.7 million (up 19.83% YoY), and the FY2025 annual result was $28.7 million, up 19.43% from the prior year.
• Share-based Compensation eased to $5.5 million in Q1 2026 per PHAT's latest filing, from $5.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $19.3 million in Q4 2023 and troughed at $5.5 million in Q1 2026.
• A 5-year average of $7.2 million and a median of $6.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation surged 189.92% in 2023, then plunged 65.35% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $6.7 million in 2022, then surged by 189.92% to $19.3 million in 2023, then sank by 65.35% to $6.7 million in 2024, then fell by 16.11% to $5.6 million in 2025, then fell by 1.35% to $5.5 million in 2026.
• Business Quant data shows PHAT's Share-based Compensation at $5.5 million in Q1 2026, $5.6 million in Q4 2025, and $9.3 million in Q3 2025.